Glucagonoma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2], Mohammed Abdelwahed M.D [3]

Overview

Secondary prevention measures of glucagonoma include routine glucagon levels and imaging at scheduled intervals after treatment.

Secondary Prevention

Guidelines from the National Comprehensive Cancer Network include the following recommendations for follow-up after treatment of a pancreatic neuroendocrine tumor:^[1]

Three to 12 months post-resection: History and physical examination, serum glucagon level, and computed tomography or magnetic resonance imaging.
More than one-year post-resection to a maximum of 10 years: history and physical examination with serum glucagon level every 6 to 12 months. Imaging studies as clinically indicated.

References

National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on February 27, 2016).

↑ Halvorson SA, Gilbert E, Hopkins RS, Liu H, Lopez C, Chu M; et al. (2013). “Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome”. J Gen Intern Med. 28 (11): 1525–9. doi:10.1007/s11606-013-2490-5. PMC 3797362. PMID 23681843.

Template:WH Template:WS

[pmid23681843-1] Halvorson SA, Gilbert E, Hopkins RS, Liu H, Lopez C, Chu M; et al. (2013). “Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome”. J Gen Intern Med. 28 (11): 1525–9. doi:10.1007/s11606-013-2490-5. PMC 3797362. PMID 23681843.

[1]